LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/James H. Mackaness: New CFO at Invuity
People In The News

James H. Mackaness: New CFO at Invuity

August 25, 2015 1 min read Premium comments

Advertisement

James H. Mackaness: New CFO at Invuity
James H. Mackaness

James H. Mackaness, a seasoned medical device and operations executive, has been named chief financial officer (CFO) of Invuity, Inc. Mackaness has amassed more than 20 years of experience, and specializes in financial and strategic planning, public reporting and controls, mergers and acquisitions, and operations management within the medical device and technology industries.

“We are very pleased to have Jim joining Invuity at this time as he brings a rare combination of skills that is well suited to our company profile, ” said Philip Sawyer, president and CEO of Invuity, in the August 10, 2015 news release.

According to the news release, “Most recently, Mackaness served as Chief Financial Officer and Chief Operating Officer for Mountain View, Calif.-based IRIDEX Corp., a publicly traded medical device company. Prior to IRIDEX, Mackaness was the CFO at two privately held companies one of which was sold to Cisco Systems where he went on to assume a business development role. Early in his career, he was an audit manager for Ernst & Young LLP.”

Mackaness told OTW, “Invuity is filling an important unmet need that has the potential to transform the standard of care in surgery. Going public is a huge milestone for the company, and a critical step towards becoming the market leader in surgical illumination technology. I am excited to work with Philip, the team, and our partners to continue driving the company’s business forward.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy